Clover Wolf Capital – Limited Buys 117,489 Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) Stock

Pluristem Therapeutics Inc. (NASDAQ:PSTI) major shareholder Clover Wolf Capital – Limited bought 117,489 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were bought at an average cost of $7.57 per share, with a total value of $889,391.73. Following the completion of the purchase, the insider now directly owns 2,601,311 shares of the company’s stock, valued at approximately $19,691,924.27. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Clover Wolf Capital – Limited also recently made the following trade(s):

  • On Thursday, June 18th, Clover Wolf Capital – Limited acquired 49,000 shares of Pluristem Therapeutics stock. The stock was acquired at an average cost of $7.36 per share, with a total value of $360,640.00.
  • On Wednesday, June 10th, Clover Wolf Capital – Limited acquired 25,000 shares of Pluristem Therapeutics stock. The stock was acquired at an average cost of $6.91 per share, with a total value of $172,750.00.
  • On Monday, June 8th, Clover Wolf Capital – Limited acquired 178,717 shares of Pluristem Therapeutics stock. The stock was acquired at an average cost of $7.36 per share, with a total value of $1,315,357.12.
  • On Thursday, June 4th, Clover Wolf Capital – Limited acquired 7,610 shares of Pluristem Therapeutics stock. The stock was acquired at an average cost of $7.86 per share, with a total value of $59,814.60.
  • On Sunday, May 31st, Clover Wolf Capital – Limited purchased 1,797 shares of Pluristem Therapeutics stock. The shares were purchased at an average cost of $7.95 per share, with a total value of $14,286.15.
  • On Wednesday, May 27th, Clover Wolf Capital – Limited purchased 90,000 shares of Pluristem Therapeutics stock. The shares were purchased at an average cost of $8.14 per share, with a total value of $732,600.00.

Shares of NASDAQ:PSTI opened at $8.84 on Wednesday. Pluristem Therapeutics Inc. has a twelve month low of $2.82 and a twelve month high of $13.29. The company’s 50 day moving average is $8.28 and its 200 day moving average is $5.75. The company has a current ratio of 2.47, a quick ratio of 2.47 and a debt-to-equity ratio of 0.06. The company has a market cap of $219.17 million, a PE ratio of -2.68 and a beta of 2.60.

Several analysts have commented on the stock. Dawson James reissued a “buy” rating on shares of Pluristem Therapeutics in a research report on Wednesday, April 15th. Maxim Group restated a “buy” rating and set a $12.00 price objective on shares of Pluristem Therapeutics in a report on Friday, May 15th. HC Wainwright restated a “buy” rating and set a $15.50 price objective on shares of Pluristem Therapeutics in a report on Thursday, May 14th. Zacks Investment Research downgraded shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Jefferies Financial Group initiated coverage on shares of Pluristem Therapeutics in a report on Friday, June 19th. They set a “buy” rating and a $12.00 price objective on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $12.20.

A number of large investors have recently modified their holdings of PSTI. Renaissance Technologies LLC increased its holdings in Pluristem Therapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 273,419 shares of the biotechnology company’s stock worth $1,077,000 after buying an additional 87,188 shares during the period. Jane Street Group LLC increased its holdings in Pluristem Therapeutics by 303.9% in the 4th quarter. Jane Street Group LLC now owns 67,349 shares of the biotechnology company’s stock worth $265,000 after buying an additional 50,674 shares during the period. Levin Capital Strategies L.P. acquired a new position in Pluristem Therapeutics in the 1st quarter worth approximately $37,000. Finally, ETF Managers Group LLC increased its holdings in Pluristem Therapeutics by 9.8% in the 1st quarter. ETF Managers Group LLC now owns 64,853 shares of the biotechnology company’s stock worth $206,000 after buying an additional 5,764 shares during the period. Institutional investors own 7.82% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Featured Article: What is a Lock-Up Period?

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.